Surgery and the Immune Response

Salo, Matti

doi:10.1007/978-1-4613-0919-2_32

Cited by 2 publications

(2 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient group is fairly homogeneous in terms of age, menopausal status, clinical stage, nutritional and performance status and previous systemic therapy. Also the time from surgery is long enough to have permitted recovery from possible immunological changes caused by anesthesia or surgery [20]. Our results indicate that toremifene, unlike estrogens, might stimulate the cell-mediated immunity of the patients.…”

Section: Introductionmentioning

confidence: 79%

See 1 more Smart Citation

The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene

Valavaara

Tuominen

Toivanen

1990

Cancer Immunol Immunother

View full text Add to dashboard Cite

The immune status of breast cancer patients was followed during antiestrogen treatment for at least 1 year or until progression of the disease. Twelve post-menopausal women with advanced estrogen-receptor-positive breast cancer were treated with a novel antiestrogen, toremifene. Immune functions were determined before the start of the treatment and at 3, 6, and 12 months. For NK cell cytotoxicity testing there were 74 healthy controls and for T cell subset measurements 28 healthy controls. No statistically significant changes in the T cell subsets or NK cell cytotoxicity were observed during treatment. However, throughout toremifene treatment patients had fewer CD4 cells (T helper lymphocytes) than did the controls. Cancer patients had higher pretreatment B cell values than the controls, P = 0.01, but during the first months of toremifene treatment B cell values decreased and remained within the normal range thereafter. A positive effect on mitogen-stimulation tests with phytohemagglutinin (PHA) and concanavalin A (ConA) was observed during the first months of treatment (P = 0.01 for PHA and 0.03 for log [ConA] and a stabilization at the higher level thereafter. These results indicate that toremifene has a stimulatory effect on cell-mediated immunity in breast cancer patients.

show abstract

Section: Introductionmentioning

confidence: 79%

“…The time from operation to the beginning of toremifene treatment varied from 3 weeks to 14 years, with a median of 24.5 months. So the effects of anesthesia and surgery, which are of short duration [20], were excluded. Seven patients had received postoperative radiotherapy after mastectomy 1.5-14 years before entry to the study.…”

Section: Methodsmentioning

confidence: 99%

The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene

Valavaara

Tuominen

Toivanen

1990

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

Immunosuppressive effects of blood transfusion in anaesthesia and surgery

Salo

1988

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

The immunosuppressive effects of blood transfusion at surgical operations become manifest as enhanced graft survival, increased cancer recurrence and decreased patient survival, and increased susceptibility tn postoperative infections. Blood transfusion in transplant recipients no longer offers this advantage when cyclosporine A is used. The deleterious effects of blood transfusion on the prognosis of some cancers found in the statistical analyses of retrospective studies are considered to be of increasing clinical importance. 'I'hercforc, unnecessary blood transfusions should be avoided and special attention directed to the use of autologous blood. Leucocyte-free red blood concentrates are the least immunosuppressive homologous blood preparations. Conventional red blood cell concentrates may also be used in cancer patients until ongoing prospective randomized studies confirm that there is a true association between the use of homologous blood and inreased recurrence of cancer.

show abstract

Surgery and the Immune Response

Cited by 2 publications

References 69 publications

The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene

The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene

Immunosuppressive effects of blood transfusion in anaesthesia and surgery

Contact Info

Product

Resources

About